(Q36346494)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Targeting ROR1 identifies new treatment strategies in hematological cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Hanna Karvonen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Wilhelmiina Niininen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Astrid Murumägi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

1 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

Biochemical Society Transactions

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

457-464

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Ror1-Ror2 complexes modulate synapse formation in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

ROR1, an embryonic protein with an emerging role in cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The complex world of WNT receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Wnt5a Signaling in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Targeting malignant B cells with an immunotoxin against ROR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

New insights into pre-BCR and BCR signalling with relevance to B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20160272

21 January 2018

Identifiers

DOI

10.1042/BST20160272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28408486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference